HD-IL-2 administration has been associated with life-threatening toxicities such as vascular leak syndrome (VLS) and pulmonary edema [10], so most patients do not benefit from HD-IL-2 therapy [9]. This evidence concerns the gene IL2 and pulmonary edema.